Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer

KRAS is frequently mutated in lung cancers and is associated with aggressive biology and chemotherapy resistance. Therefore, innovative approaches are needed to treat these lung cancers. Prior work implicated the IFN-stimulated gene 15 (ISG15) deubiquitinase (DUB) USP18 as having antineoplastic activity by regulating lung cancer growth and oncoprotein stability. This study demonstrates that USP18 affects the stability of the KRAS oncoprotein. Interestingly, loss of USP18 reduced KRAS expression, and engineered gain of USP18 expression increased KRAS protein levels in lung cancer cells. Using the protein synthesis inhibitor cycloheximide, USP18 knockdown significantly reduced the half-life of KRAS, but gain of USP18 expression significantly increased its stability. Intriguingly, loss of USP18 altered KRAS subcellular localization by mislocalizing KRAS from the plasma membrane. To explore the biologic consequences, immunohistochemical (IHC) expression profiles of USP18 were compared in lung cancers of KrasLA2/+ versus cyclin E engineered mouse models. USP18 expression was higher in Kras-driven murine lung cancers, indicating a link between KRAS and USP18 expression in vivo. To solidify this association, loss of Usp18 in KrasLA2/+/Usp18−/− mice was found to significantly reduce lung cancers as compared with parental KrasLA2/+ mice. Finally, translational relevance was confirmed in a human lung cancer panel by showing that USP18 IHC expression was significantly higher in KRAS-mutant versus wild-type lung adenocarcinomas. Implications: Taken together, this study highlights a new way to combat the oncogenic consequences of activated KRAS in lung cancer by inhibiting the DUB USP18. Mol Cancer Res; 15(7); 905–14. ©2017 AACR.

[1]  Jun Yu,et al.  The ISG15-specific protease USP18 regulates stability of PTEN , 2016, Oncotarget.

[2]  E. Dmitrovsky,et al.  Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas , 2015, BMC Cancer.

[3]  Q. Dou,et al.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review , 2015, Expert opinion on therapeutic patents.

[4]  E. Dmitrovsky,et al.  CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. , 2015, Cancer research.

[5]  V. Pant,et al.  Limiting the power of p53 through the ubiquitin proteasome pathway , 2014, Genes & development.

[6]  K. Knobeloch,et al.  Molecular characterization of ubiquitin‐specific protease 18 reveals substrate specificity for interferon‐stimulated gene 15 , 2014, The FEBS journal.

[7]  J. Pignon,et al.  Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? , 2014, Lung cancer.

[8]  S. Desai,et al.  ISGylation governs the oncogenic function of Ki-Ras in breast cancer , 2014, Oncogene.

[9]  A. Chinnaiyan,et al.  KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. , 2014, Neoplasia.

[10]  Dharini van der Hoeven,et al.  Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission , 2012, Molecular and Cellular Biology.

[11]  Andrew M. Piggott,et al.  Staurosporines Disrupt Phosphatidylserine Trafficking and Mislocalize Ras Proteins* , 2012, The Journal of Biological Chemistry.

[12]  E. Dmitrovsky,et al.  Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target , 2012, Molecular Cancer Therapeutics.

[13]  V. Quesada,et al.  Deubiquitinases in cancer: new functions and therapeutic options , 2012, Oncogene.

[14]  Sara Schmitt,et al.  Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy. , 2011, Current topics in medicinal chemistry.

[15]  C. Der,et al.  Inhibition of Ras for cancer treatment: the search continues. , 2011, Future medicinal chemistry.

[16]  S. Pestka,et al.  Interferon-β Signaling Contributes to Ras Transformation , 2011, PloS one.

[17]  A. Balmain,et al.  Progressive Genomic Instability in the FVB/KrasLA2 Mouse Model of Lung Cancer , 2011, Molecular Cancer Research.

[18]  F. McCormick,et al.  Therapeutic strategies for targeting ras proteins. , 2011, Genes & cancer.

[19]  E. Dmitrovsky,et al.  Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. , 2010, Cancer research.

[20]  D. Malo,et al.  N-Ethyl-N-Nitrosourea–Induced Mutation in Ubiquitin-Specific Peptidase 18 Causes Hyperactivation of IFN-αβ Signaling and Suppresses STAT4-Induced IFN-γ Production, Resulting in Increased Susceptibility to Salmonella Typhimurium , 2010, The Journal of Immunology.

[21]  Jiří Drábek,et al.  Clinical Relevance of KRAS in Human Cancers , 2010, Journal of biomedicine & biotechnology.

[22]  E. Dmitrovsky,et al.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.

[23]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[24]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[25]  R. Assoian,et al.  Transcriptional regulation of the cyclin D1 gene at a glance , 2008, Journal of Cell Science.

[26]  O. Bachs,et al.  Identification of Essential Interacting Elements in K-Ras/Calmodulin Binding and Its Role in K-Ras Localization* , 2008, Journal of Biological Chemistry.

[27]  S. Kitareewan,et al.  UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation , 2008, Molecular Cancer Therapeutics.

[28]  U. Rapp,et al.  Ras oncogenes and their downstream targets. , 2007, Biochimica et biophysica acta.

[29]  Lewis A. Chodosh,et al.  Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis , 2007, Nature Cell Biology.

[30]  E. Dmitrovsky,et al.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas , 2007, Proceedings of the National Academy of Sciences.

[31]  N. Sze,et al.  HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Shuai,et al.  UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity , 2006, The EMBO journal.

[33]  J. Minna,et al.  High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. , 2006, Cancer research.

[34]  E. Dmitrovsky,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers , 2004, Clinical Cancer Research.

[35]  R. Krug,et al.  The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-α/β-induced ubiquitin-like protein , 2004 .

[36]  Robert G. Parton,et al.  Direct visualization of Ras proteins in spatially distinct cell surface microdomains , 2003, The Journal of cell biology.

[37]  S. Orkin,et al.  Dysregulation of protein modification by ISG15 results in brain cell injury. , 2002, Genes & development.

[38]  Dong-er Zhang,et al.  UBP43 (USP18) Specifically Removes ISG15 from Conjugated Proteins* , 2002, The Journal of Biological Chemistry.

[39]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[40]  R. Krug,et al.  Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)‐induced ubiquitin‐like ISG15 protein , 2001, The EMBO journal.

[41]  J. Hancock,et al.  H-ras but Not K-ras Traffics to the Plasma Membrane through the Exocytic Pathway , 2000, Molecular and Cellular Biology.

[42]  Y. Kloog,et al.  Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. , 1999, Biochimica et biophysica acta.

[43]  T. Morimoto,et al.  Endomembrane Trafficking of Ras The CAAX Motif Targets Proteins to the ER and Golgi , 1999, Cell.

[44]  F. McCormick,et al.  Analysis of RAS oncogene mutations in human lymphoid malignancies. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[46]  M. Serrano,et al.  Senescence in tumours: evidence from mice and humans , 2010, Nature Reviews Cancer.

[47]  R. Krug,et al.  The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.